BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33823155)

  • 1. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
    Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
    J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKN2A germline mutations in familial pancreatic cancer.
    Bartsch DK; Sina-Frey M; Lang S; Wild A; Gerdes B; Barth P; Kress R; Grützmann R; Colombo-Benkmann M; Ziegler A; Hahn SA; Rothmund M; Rieder H
    Ann Surg; 2002 Dec; 236(6):730-7. PubMed ID: 12454511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.
    Potjer TP; van der Stoep N; Houwing-Duistermaat JJ; Konings IC; Aalfs CM; van den Akker PC; Ausems MG; Dommering CJ; van der Kolk LE; Maiburg MC; Spruijt L; Wagner A; Vasen HF; Hes FJ
    BMC Res Notes; 2015 Jun; 8():264. PubMed ID: 26111702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations.
    Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S
    Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel CDKN2A variant (p16
    Li C; Liu T; Liu B; Hernandez R; Facelli JC; Grossman D
    Pigment Cell Melanoma Res; 2019 Sep; 32(5):734-738. PubMed ID: 31001908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
    McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
    Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial head and neck cancer: molecular analysis of a new clinical entity.
    Yu KK; Zanation AM; Moss JR; Yarbrough WG
    Laryngoscope; 2002 Sep; 112(9):1587-93. PubMed ID: 12352668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
    McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
    Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma.
    Ghiorzo P; Gargiulo S; Pastorino L; Nasti S; Cusano R; Bruno W; Gliori S; Sertoli MR; Burroni A; Savarino V; Gensini F; Sestini R; Queirolo P; Goldstein AM; Scarrà GB
    Hum Mol Genet; 2006 Sep; 15(18):2682-9. PubMed ID: 16893909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
    Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
    J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel CDKN2A in-frame deletion associated with pancreatic cancer-melanoma syndrome.
    Bottillo I; Valiante M; Menale L; Paiardini A; Papi L; Janson G; Sestini R; Iorio A; De Simone P; Frascione P; Grammatico P
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline
    Jouenne F; Chauvot de Beauchene I; Bollaert E; Avril MF; Caron O; Ingster O; Lecesne A; Benusiglio P; Terrier P; Caumette V; Pissaloux D; de la Fouchardière A; Cabaret O; N'Diaye B; Velghe A; Bougeard G; Mann GJ; Koscielny S; Barrett JH; Harland M; Newton-Bishop J; Gruis N; Van Doorn R; Gauthier-Villars M; Pierron G; Stoppa-Lyonnet D; Coupier I; Guimbaud R; Delnatte C; Scoazec JY; Eggermont AM; Feunteun J; Tchertanov L; Demoulin JB; Frebourg T; Bressac-de Paillerets B
    J Med Genet; 2017 Sep; 54(9):607-612. PubMed ID: 28592523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.
    Christodoulou E; Visser M; Potjer TP; van der Stoep N; Rodríguez-Girondo M; van Doorn R; Gruis N
    Fam Cancer; 2019 Oct; 18(4):439-444. PubMed ID: 31203567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer.
    Kimura H; Klein AP; Hruban RH; Roberts NJ
    Pancreas; 2021 Sep; 50(8):1123-1130. PubMed ID: 34714275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.
    Yang XR; Rotunno M; Xiao Y; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Bennett H; Graham C; Sampson JN; Malasky M; Vogt A; Zhu B; Bianchi-Scarra G; Bruno W; Queirolo P; Fornarini G; Hansson J; Tuominen R; Burdett L; Hicks B; Hutchinson A; Jones K; Yeager M; Chanock SJ; Landi MT; Höiom V; Olsson H; Gruis N; Ghiorzo P; Tucker MA; Goldstein AM
    Hum Genet; 2016 Nov; 135(11):1241-1249. PubMed ID: 27449771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
    Buecher B; Gauthier-Villars M; Desjardins L; Lumbroso-Le Rouic L; Levy C; De Pauw A; Bombled J; Tirapo C; Houdayer C; Bressac-de Paillerets B; Stoppa-Lyonnet D
    Fam Cancer; 2010 Dec; 9(4):663-7. PubMed ID: 20842456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
    Holland EA; Schmid H; Kefford RF; Mann GJ
    Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial cutaneous melanoma.
    Hansson J
    Adv Exp Med Biol; 2010; 685():134-45. PubMed ID: 20687502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation.
    Scaini MC; Rossi E; de Siqueira Torres PL; Zullato D; Callegaro M; Casella C; Quaggio M; Agata S; Malacrida S; Chiarion-Sileni V; Vecchiato A; Alaibac M; Montagna M; Mann GJ; Menin C; D'Andrea E
    Mutat Res; 2009 Dec; 671(1-2):26-32. PubMed ID: 19712690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.